INTRODUCTION
Prostate cancer is the most common form of cancer to affect men in the UK. Current survival rates suggest that of those men who develop the disease approximately eighty four percent will survive for 10 or more years. For some men, however, the disease is far more aggressive. Ongoing studies are in place to try to understand the mechanisms responsible for this difference between slow growing, indolent tumors, and the aggressive disease. Many of these studies have focussed on the role of soluble growth factors as modulators of the tumor microenvironment thereby supporting aggressive metastatic forms of the disease. There is, however, a growing precedent to explore the role of extracellular vesicles (EV) in this process.
All cells are capable of secreting vesicles into the Topic: How does the prostate cancer microenvironment affect the metastatic process and/or treatment outcome?
Open Access extracellular space. Vesicle secretion becomes elevated when cells are subjected to cellular stress [1, 2] , which can also result in altered molecular cargo within the vesicle [3] . This is particularly relevant in cancer where stress can come from the hypoxic environment, nutrient deficiency, altered extracellular matrix, and other environmental factors. Such vesicles are often regarded as one of two broad subtypes, microvesicles and exosomes. Microvesicles are large, tending to be greater than 200 nm in diameter, dense, and are formed from outward budding of the plasma membrane. Exosomes are much smaller, typically 30 to 150 nm in diameter, float at a characteristic density of 1.1 to 1.2 g/mL [4] and originate within multivesicular endosomes [4] . The secretion of small, exosome-like, vesicles has also been reported from the plasma membrane [5] . It remains a challenge to accurately define vesicle subtypes based on size alone. To aid researchers, the International Society for Extracellular Vesicles has released a position paper detailing the minimal experimental requirements for defining EV [6] . Although, the challenge of defining EV subtypes remains, and is further compounded by overlap in EV composition [7] , hence the term EV is often used. The majority of EV present within both cell conditioned media or biological fluids tend to be small [8] , suggesting a predominant exosome-like population. The biological significance of any one EV subtype compared to another, however, remains unknown.
The role of EV in cancer has been the studied intensively over recent years [9] . Relatively few of these studies have focused on the potential role of EV, and more specifically exosomes, in prostate cancer. In this current article, we review past studies into the role of exosomes, in diverse malignancies, to identify their potential functions in disease processes of relevance to prostate cancer.
EXOSOME-MEDIATED ANGIOGENESIS
Angiogenesis, or the formation of new blood vessels from pre-existing vasculature, is a vital component in numerous physiological and pathological responses. A variety of angiogenic signals are required to drive endothelial maturation and subsequent re-organisation with vascular smooth muscle cells and pericytes to form a functional vessel network [10] , thereby allowing nutrient and waste product exchange [11, 12] . In cancer, multiple modulators of vascular remodelling contribute to tumor growth and progression [13] . Once a tumor lesion forms it will become hypoxic and nutrient deprived. The secretion of growth factors activates normal surrounding quiescent cells, to initiate a cascade of events that become quickly dysregulated. This involves an "angiogenic" switch, regulated by both anti-and pro-angiogenic cytokines, examples of which include endothelial growth factor, fibroblast growth factor (FGF), hepatocyte growth factor (HGF), plateletderived growth factor (PDGF) and vascular endothelial growth factor (VEGF) [14] [15] [16] . These responses may initially provide the tumor with more nutrients and oxygen, however, the structural organization of the vessel network is poor, and the continuously remodeled tumor vasculature is disorganized and leaky [17] . This causes irregular blood flow and provides invasive tumors with access to the circulatory system.
PRO-ANGIOGENIC ACTIVITY OF EXOSOME-ASSOCIATED PROTEINS
Cancer cell-derived EV have been shown in several studies to promote angiogenesis. In the case of prostate cancer it is well established that c-Src tyrosine kinase, insulin-like growth factor 1 receptor (IGF-1R) and focal adhesion kinase (FAK) play important roles in tumor growth and disease progression [18] . Src-family kinases are normally expressed in prostatic epithelium and reported to transform normal cells when constitutively active and up-regulated during disease initiation and progression [19] . Cross-talk between Src and IGF-1R has previously been shown to promote angiogenesis [20] . It has been reported that Src, IGF-1R and FAK are enriched in prostate cancer exosomes [21] . Src and c-Src are also present in plasma exosomes derived from prostate tumor bearing mice; suggesting that Src-enriched exosomes can promote angiogenesis in vivo. Src is known to stimulate transcription of VEGF and modulate angiogenesis [22] whilst IGF-1R has been demonstrated to induce VEGF-C expression and stimulate angiogenesis [23] . These observations suggest that prostate cancer exosomes enriched with c-Src, IGF-1R and FAK may be able to stimulate angiogenic activity within the tumor microenvironment.
Prostate cancer EV are also likely to be capable of delivering growth factors with known pro-angiogenic function. For instance, EV from aggressive prostate cancer cells have been shown to contain urokinasetype plasminogen activator (uPA) [24] , known to be involved in activation of the protease plasminogen which is responsible for vascular remodeling [25] . Addition of uPA positive vesicles to less aggressive prostate cancer cells stimulated cell migration and invasiveness [24] . Although this study did not investigate the impact of uPA positive vesicles on the ability of treated cells to drive angiogenesis, it is conceivable that prostate cancer derived EV can support endothelial tubule formation via delivery of pro-angiogenic growth factors. Additional pro-angiogenic factors have been identified on EV from a variety of different cancer cell types and are summarized in Table 1 . Further studies are required to ascertain whether these factors are present on prostate cancer EV.
DELIVERY OF PRO-ANGIOGENIC RNAS BY EXOSOMES
Whilst direct evidence of RNA delivery by prostate cancer EV is currently lacking, EV from several cancer types are known to be enriched with mRNA transcripts related to pro-angiogenic function that can then be translated by recipient cells [26, 27] . Similar studies have shown an enhanced proliferative impact on endothelial cells [28, 29] and enhanced tubule formation within 3D cell cultures [28] . The transfer of exosomal miRNA, such as miRNA-92a and miR-17-92, may also play a role in this process [30] and miR-17-92 may play a role in this process [30] . Furthermore, transmittance of the miR-17-92 cluster from EV to endothelial cells has been shown to attenuate endothelial expression of integrin α v resulting in enhanced endothelial cell migration and tube formation [30] . Numerous studies highlight a role of cancer exosomes in delivery of RNAs to endothelial cells, thereby promoting angiogenesis, and it is therefore likely that prostate cancer exosomes share this functionality.
HYPOXIC TUMOR-DERIVED EXOSOMES ENHANCE ANGIOGENESIS
As a tumor grows diffusion distances from the existing vascular supply increase, resulting in hypoxia.
Sustained growth of the tumor mass often requires new blood vessels to provide rapidly proliferating tumor cells with an adequate supply of metabolites and oxygen. Under hypoxic conditions the cellular secretome becomes altered and a proportion of these changes may reside within the exosome fraction. Exosomes derived from solid tumors, which have been cultured in hypoxic conditions, become enriched with hypoxia-regulated mRNAs and proteins such as Caveolin 1, IL-8, matrix metalloproteinase (MMP) and PDGF, and are capable of promoting angiogenesis [31] . Similarly, under hypoxic conditions, the secretion of exosomes from breast cancer [32] or leukemic cells [33] demonstrate elevated levels of exosomal miR-210, with the capacity to enhance HUVEC tube formation compared to exosomes from normoxic conditions. Although EV from hypoxic prostate cancer cells are yet to be investigated, based on this evidence, it is highly likely that the cargo of prostate cancer exosomes is also influenced by hypoxic conditions. The impact of hypoxia-derived vesicles on angiogenesis and subsequent development of prostatic tumors remains unknown.
INDIRECT EXOSOME-MEDIATED ANGIOGENESIS
In addition to direct modulation of angiogenesis within the tumor microenvironment, exosomes have the potential to regulate angiogenesis indirectly through interactions with various non-endothelial cell types. Prostate cancer exosomes, expressing transforming growth factor beta (TGFβ), can activate fibroblasts Multiple myeloma, ovarian [131, 134] A selected overview of pro-angiogenic factors previously identified on EV. Association of pro-angiogenic proteins with EV has been demonstrated in multiple cancers, but the precise involvement of some such proteins in prostate cancer remains unclear. EV: extracellular vesicles; EGFR: epidermal growth factor receptor; VEGF: vascular endothelial growth factor; Akt: protein kinase B (serine/threonine specific protein kinase); FAK: focal adhesion kinase; IGF-1R: insulin-like growth factor 1 receptor; Src: proto-oncogene tyrosine-protein kinase Src; FGF2: fibroblast growth factor 2; MMP: matrix metalloproteinase; Tspan8: tetraspanin-8; uPA: urokinase-type plasminogen activator; VEGFR: vascular endothelial growth factor receptor; vWF: von willebrand factor; RhoA: Ras homolg gene family, member A; ROCK: Rhoassociated, coiled-coil containing protein kinase; PLCγ: phospholipase C gamma resulting in elevated secretion of multiple proangiogenic factors including VEGF, HGF, FGF-2, and uPA [34, 35] . Furthermore, prostate cancer exosomes were shown to induce pro-angiogenic function within primary prostate stromal cells and were shown to facilitate in vivo tumor growth [35] . Other studies have reported cancer-associated myofibroblasts can secrete pro-angiogenic growth factors and promote angiogenesis at the primary tumor site [36] [37] [38] [39] . Also, HGF and stromal cell-derived factor-1 derived from these myofibroblasts can indirectly enhance angiogenesis by inducing the secretion of angiogenic factors from tumor cells [40, 41] .
Collectively, these studies demonstrate that exosomes derived from solid tumors, including prostate cancer, drive activation of fibroblasts to a proangiogenic phenotype.
The ability of prostate cancer exosomes to trigger secretion of pro-angiogenic factors extends to bone marrow-derived mesenchymal stem cells (BM-MSCs), which can also gain exosome-induced pro-angiogenic function [42] . Exosome-activated MSCs were shown to secrete elevated levels of HGF, VEGF and MMPs, and support the formation of endothelial vessel-like structures. Exosomes from metastatic melanomas have also been shown to interact with bone marrow progenitor cells via the tyrosine kinase MET [43] , which induced vascular leakiness at pre-metastatic sites and reprogrammed bone marrow progenitors towards a pro-vasculogenic phenotype. This "reprogramming" of the bone marrow progenitors resulted in significantly increased tumor vascular density in vivo.
A wide range of studies have demonstrated various roles of cancer exosomes in promoting angiogenesis either through direct or indirect interaction with endothelial cells. Prostate cancer exosomes are likely to be dynamic in response to hypoxia and may act as a means to deliver a variety of factors capable of supporting the formation of tumor-associated vasculature in vivo.
EXOSOME-DRIVEN TUMOR-STROMA INTERACTIONS
Stromal cells surrounding a tumor can undergo a desmoplastic response, characterized by aberrant cell growth and morphological transformation of the stroma, resulting in a more aggressive tumor microenvironment [44] . A key feature of this tumor reactive stroma is the presence of cells with a myofibroblastlike phenotype [45] . Myofibroblasts are contractile cells, characterized by the formation of α smooth muscle actin (αSMA) stress fibers [46] , loss of the spindle phenotype and formation of a hyaluronic acid pericellular coat [47] .
During wound healing myofibroblasts are present to aid wound closure. In various cancers, however, a chronic wound response can occur resulting in sustained presence of myofibroblasts within the tumor microenvironment [48] .
Cancer associated myofibroblasts display an altered phenotype compared to wound associated myofibroblasts [49] and have been termed activated fibroblasts, tumor associated fibroblasts and cancer associated fibroblasts. There is conflicting evidence as to whether myofibroblasts promote or suppress tumorigenesis. Rhim et al. [50] observed that removal of myofibroblasts from the stroma of pancreatic ductal adenocarcinoma (PDAC) in vivo results in more aggressive tumors and reduced mouse survival rates. However, the prevailing view is that stroma rich in myofibroblasts has an increased ability to drive tumor growth, angiogenesis, metastasis and treatment resistance [45, 51, 52] .
ACTIVATION AND MODULATION OF STROMAL CELLS BY EXOSOMES
Fibroblast differentiation is known to be induced by TGFβ1 via SMAD dependent and independent signaling pathways [53] [54] [55] . It has been established that exosomes secreted by prostate cancer cells express latent TGFβ1 [56] , tethered to the exosome surface via proteoglycans and capable of activating SMAD3 dependent signaling [34] . The authors demonstrate that prostate cancer derived exosomes, with greater than 6 pg TGFβ1/µg exosome, can induce fibroblast differentiation [34] . Differentiation could be sustained for at least 2 weeks in the absence of further exosome treatment, indicating the resulting myofibroblastlike phenotype is self-maintaining. In contrast, EV originating from MDA-MB231 breast cancer cells and u87 glioblastoma cells could only induce transient fibroblast differentiation [57] , potentially suggesting differences between EV from distinct tissue types.
A subsequent study by Webber et al. [35] identified that exosomal TGFβ1 induces a more aggressive, proangiogenic myofibroblast phenotype compared to the soluble form of the growth factor. These results were replicated in primary stromal cells from normal prostate tissue, resulting in a myofibroblast-like phenotype that matched that found within diseaseassociated stromal tissue. Furthermore, pre-treating normal stroma with prostate cancer derived exosomes prior to administration enhanced tumor growth in mice. In contrast, pre-treatment with soluble TGFβ1 led to tumor control. Consistent with this report, a separate study showed that metastatic rat prostate tumor EV are capable of activating primary rat prostate fibroblasts, leading to upregulation of αSMA, HGF and VEGFA [58] . Exosomes therefore appear to play a crucial role in communication between prostate cancer cells and the surrounding stroma, with exosome-associated TGFβ1 essential for inducing fibroblast differentiation towards a disease supporting phenotype.
The exact origin of disease-associated myofibroblasts remains unclear, and it has been shown that other cells are capable of myofibroblastic differentiation. MSCs, a multipotent cell type capable of generating many different types of connective tissue, can also differentiate into myofibroblasts in response to secreted factors from tumors [40] . MSCs make up 1.1% of cells within the prostate cancer stroma [59] and exhibit similar tumor promoting effects to cancer associated stroma [40, 60, 61] .
Exosomes secreted by breast [62] , ovarian [63] and gastric [64] cancer cells induce TGFβ1-dependent differentiation of adipose or cord blood derived MSCs to myofibroblasts. In addition, chronic lymphocytic leukemia exosomes have been shown to enhance tumor growth in vivo by inducing differentiation of BM-MSCs [65] . Adipose derived MSCs, meanwhile, differentiate in response to EV from metastatic breast cancer in 2D and 3D culture. This process was shown to require TGFβ dependent MAPK signaling involving phosphorylation of ERK1/2 and JNK1/2 [66] .
Chowdhury et al. [42] demonstrated that prostate cancer exosomes can also drive BM-MSC differentiation, resulting in myofibroblasts with increased VEGFA, HGF and MMP secretion, capable of enhancing cancer cell growth. Exosome differentiated BM-MSCs drove prostate cancer cell invasion in a 3D spheroid model and stimulated endothelial cell migration, proliferation and angiogenic potential. As previously observed, exosomal TGFβ1 treatment resulted in myofibroblasts with an enhanced pro-tumorigenic phenotype compared to soluble TGFβ1. Interestingly, exosomes also modulated BM-MSC derived myofibroblast expression of ITGB6 and ITGB8, encoding for components of integrins αvβ6 and αvβ8, which are involved in converting latent TGFβ1 to the active form [67, 68] . This may therefore explain how latent TGFβ1 delivered by exosomes becomes functionally active. The predominant population of myofibroblast precursors remains unclear. Regardless of the precursor cell, it is evident that prostate cancer exosomes can trigger differentiation to a stromal phenotype with disease promoting properties.
Delivery of TGFβ1 is not the only mechanism by which exosomes can stimulate pro-tumorigenic phenotypes in stromal cells. EV transfer of mRNA, miRNA and membrane proteins have all been implicated. For instance, acute myeloid leukemia cell exosomes promote proliferation and migration of bone marrow stromal cells via transfer of IGF-IR mRNA [69] . Similar results have been shown in solid cancers whereby exosomal miRNAs regulate stromal cell behavior. Metastatic breast cancer cells, for example, were shown to enhance vascular permeability, and promote tumor metastasis, via the suppression of the tight junction protein ZO-1 by exosome delivered miR-105 [70] . Gastric cancer exosomes stimulate primary mouse liver myofibroblasts and hepatic pericytes by exosome mediated delivery of the membrane protein epidermal growth factor receptor (EGFR) [71] . After insertion into the stromal cell membrane, where it co-localizes with E-cadherin, EGFR activates HGF secretion by potentially suppressing upstream miRNAs such as miR-26a/b. The subsequent increase in HGF secretion promotes gastric cancer cell proliferation, migration and invasion.
Exosomes are not the only EV subgroup shown to alter the prostate stroma phenotype. Prostate cancer cells also secrete large oncosomes, EV between 100-400 nm in diameter [72] , which have sustained AKT1 activity [73, 74] . A recent study by Minciacchi et al. [75] reported that internalization of large oncosomes by prostate fibroblasts resulted in the induction of a αSMA-positive myofibroblast phenotype. Interestingly, induction of other myofibroblast markers, such as MMP1, thrombospondin-1 (TSP-1) and TGFβ1 did not occur, potentially suggesting that oncosomes induce a distinct myofibroblast-like phenotype. Analysis of transcription factor DNA binding in treated prostate fibroblasts highlighted that MYC binding was essential for this induction of a myofibroblast-like phenotype. The mechanism by which large oncosomes stimulate MYC-DNA binding has not yet been elucidated, however, as MYC has not been found to be present inside the EV it appears MYC is activated rather than delivered. This study also explored the impact of large oncosomes in vivo and found that prostate fibroblasts pre-treated with oncosomes facilitated enhanced tumor growth. These findings are similar to the earlier results obtained with exosomes and lend support to the critical role of diverse vesicle subtypes in tumorstroma communication in prostate cancer.
SECRETION OF STROMA-DERIVED EXOSOMES
Stromal cells activated by cancer cell secreted EV can initiate a positive feedback mechanism via release of stromal cell EV which promote tumorigenesis after internalization by tumor cells. A study by Josson et al. [76] highlighted this cyclical system in prostate cancer. Activated prostate fibroblasts were shown to release miR-409 containing EV, which are taken up by prostate cancer cells. Upon EV internalization miR-409 downregulates the tumor suppressors Ras suppressor 1 and stromal antigen 2, promoting cancer cell tumorigenesis and stimulating EMT and stemness in epithelial cells. This effect can also be observed in other tissues. For example, activated PDAC fibroblasts secrete ANXA6 positive EV containing the ANXA6/LRP1/TSP1 complex. Uptake of these EV by PDAC cells was shown to enhance tumorigenesis by stimulating cancer cell migration and driving tumor growth in vivo [77] . Activation of the Wntplanar cell polarity (PCP) pathway, and subsequent stimulation of cell motility and metastasis, can also be induced by stromal cell EV. Luga et al. [78] determined that CD81 + vesicles secreted from activated fibroblasts are capable of activating the Wnt-PCP pathway in breast cancer cells via transfer of Wnt11.
Stromal cells can also confer chemoresistance on surrounding tumor cells via EV communication.
Activated fibroblasts resistant to the chemotherapy drug Gemcitabine (GEM) release exosomes containing miR-146a and mRNA for its upstream transcription factor Snail [79] . Incubation of PDAC cells with exosomes from GEM treated fibroblasts results in increased levels of Snail mRNA and miR146a in the cancer cells, leading to cell proliferation and chemoresistance. Similar findings have been observed in colorectal [80] and breast cancers [81] , with the latter study identifying activation of antiviral signaling pathways through stimulation of the pattern recognition receptor RIG-I by exosomal RNA. RIG-I activates STAT1 dependent signaling which cooperates with NOTCH3 to mediate NOTCH target gene transcription, supporting maintenance of therapy resistant tumor initiating cells.
Activation of stromal cells by cancer cell-derived exosomes results in a pro-proliferative and proangiogenic stromal phenotype. In turn, EV and exosomes from activated stromal cells may then drive surrounding cancer cells towards a more aggressive, chemoresistant, phenotype. This suggests a network of reciprocal communication based on EV exists to exacerbate disease.
EXOSOME MODULATION OF MYELOID CELLS
There have been numerous studies demonstrating immunological control by EV, as reviewed previously [9] .
Despite such studies, there is a surprising paucity of information relating to prostate cancer exosomes and their influence on myeloid cells. This topic is highly relevant, however, as the presence of CD14+ macrophages and chronic inflammation within the microenvironment is a key risk factor in prostate cancer [82] .
EXOSOME-MEDIATED ANTIGEN PRESENTATION
Some of the early discoveries of exosome function have centered on their potential as immune-activating factors [4] , where professional antigen presenting cells derived from monocyte precursors were able to secrete exosomes carrying MHC-peptide complexes that were functional in T cell stimulation [83] . Antigen presenting cells (APC), educated with cancer antigens in the form of protein or peptide fragments, therefore produce nanovesicles as APC-surrogates to disseminate the activation of T cells. Isolated APC-exosomes can also be manipulated directly, by pulsing with antigenic peptides of desired specificity, and this scheme has been proposed as a cancer vaccine strategy [84] . APC can, however, also receive a complex set of antigenic information in the form of exosomes secreted by tumor cells [85, 86] , providing not only tumor-associated antigens but importantly additional information such as cellular stress signals (e.g. heat shock proteins [87] ), or even encapsulated RNA [88] , to modulate APC-phenotype and control subsequent functions. Some researchers argue that cancer cell-derived exosomes may be an advantageous form of antigen delivery to APCs in vivo [89] . There are, however, conflicting examples where the interaction of cancer-exosomes with myeloid cells may lead to disease exacerbating effects.
Amongst the earliest examples are reports detailing the skewing of dendritic cell differentiation away from a competent antigen presentation phenotype, and towards TGFβ producing myeloid cells capable of negatively regulating T cell responses [90, 91] . More recent reports also point to this phenomenon, where monocytes stimulated with cancer cell-derived EV become alternatively-activated/M2-type macrophages, expressing elevated levels of VEGF, IL6, Cox2, and arginase-1 amongst many other tumor-supportive factors [92, 93] . Similar modulation of myeloid cells are seen using pancreatic cancer exosomes, giving a suppressive CD14 + HLA-DR low/neg phenotype akin to those elevated within the circulation of patients [94] . Similarly, myeloma-derived EV present within the bone marrow microenvironment can activate myeloid-derived suppressor cells (MDSC) and promote progression [95] . In acute myeloid leukemia, vesicles may play a role in modulating normal myeloporesis and select for cells destined for suppressor-like differentiation [96, 97] . It currently remains unclear as to whether this latter phenomenon is also true of solid cancers.
MECHANISMS OF MYELOID ACTIVATION BY EV
Whilst there remains much to be learned about how EV exert such influences on myeloid cells, evidence points to delivery of EV-associated ligands to trigger signaling cascades mediated through toll-like [98, 99] or other receptors [100, 101] . Moreover, there is a likely additional effect of EV-encapsulated RNAs which may also be delivered to myeloid cells. In one elegant experimental system, cancer cells were engineered to express Cre-recombinase. Cre mRNA was detectable in various EV sub-fractions secreted by these cells, with the predominant EV type appearing to be exosome-like. Transplantation of these cells into mice with a Cre-reporter background led to recombination events at the tumor site, as indicated by β-galactosidase expression following receipt of vesicular Cre mRNA. These Cre-recombined cells were 90% CD45 + leukocytes, principally of a Gr1 + CD11b + MDSC phenotype [102] . The MDSC which had taken up vesicular RNA exhibited more potent suppressive functions compared to their counterparts that had not. The study highlights the in vivo transfer of vesicle-encapsulated RNA to myeloid cells within the tumor microenvironment, resulting in enhanced immune-suppressive function of MDSC.
The influence of EV may, however, not be limited to the local environment. In a highly metastatic breast cancer model EV were again taken up principally by CD45 + bone marrow-derived cells present at distant sites of the lung and liver. These myeloid cells were implicated thereafter in aiding the colonization of these organs by metastasizing cells. Part of this effect may also be due to localized natural killer and T cell suppressive effects attenuating anti-cancer immunity in the premetastatic organs [103] . Dissemination of EV may be more limited in some other cancer types, like glioma, where influences on myeloid phenotypes are not always found in the periphery [104] . In one study, attenuating TLR2-dependent interaction between cancer exosome and MSDS was an effective strategy for limiting MDSC numbers and activation in vivo, and in fact potentiated the effect of chemotherapeutics that would otherwise lead to heightened release of MDSC-activating vesicles. Preventing vesicle effects on MDSC may be a worthwhile therapeutic approach to consider [99] .
If lessons are to be gained from these studies of other diverse cancer types, it is indeed likely that EV of prostate cancer origin may also exert local and possibly distant influences on the myeloid cell components of tissues, and profoundly impact the course of the disease. New studies are, however, required in order to examine this further.
EXOSOME DRIVEN METASTASIS AND MULTIDRUG RESISTANCE
A key step in the progression of various cancers is the invasion of cancer cells into surrounding tissues and subsequent metastasis from the primary tumor site.
The 5-year survival rates of patients with prostate cancer drop dramatically following metastasis from the primary tumor. The primary site of metastasis of prostate cancer is the bone; such metastasis remains incurable. An increased concentration of circulating microvesicles has been reported in in vivo models of metastatic prostate cancer [74] and studies by Peinado et al. [43] have demonstrated a role of exosomes in the support of tumor metastasis to the bone.
EXOSOME-MEDIATED REGULATION OF MMPS
Cancer cell invasion, and disease progression, has been linked to an altered expression of MMPs, key regulators of the extracellular matrix. Fibronectinmediated binding of exosomes to myeloma cells has been shown to activate p38 and ERK signaling, resulting in elevate expression of DKK1 and MMP-9 and subsequent myeloma progression [105] . More recently, it has been shown that prostate cancer exosomes can regulate MMP-9 expression within osteoclast precursor cells and impair osteoclastic differentiation [106] . Collectively these studies suggest a role of prostate cancer exosomes in the modulation of the bone environment, and subsequent preparation of the metastatic site.
Proteomic analyses have revealed that both cell surface-anchored and soluble matrix metalloproteinases are present in EV isolated from either cell conditioned media or from biofluids [107] . Such vesicular-associated MMPs have been shown to be proteolytically active, and may play a variety of functional roles including direct interaction or cleavage of extracellular matrix proteins or removal of membrane-anchored receptors from target cells [108] . This is supported by further evidence from Hakulinen et al. [109] demonstrating that cancer exosomes can express functionally active MMP-14.
It has long been recognized that platelets can play a role in tumor progression by promoting angiogenesis, resulting in leaky capillaries, and therefore facilitating tumor metastasis. The mechanism of their action has however remained unclear until relatively recently. In a study by Janowska-Wieczorek et al. [110] , it was shown that platelet-derived EV, and exosomes released from α-granules, can contribute to metastatic spread via phosphorylation of mitogen activated protein kinase p42/44 and serine/threonine kinase as well as the expression of membrane type 1-MMP (MT1-MMP). The authors also showed that platelet-derived EV are capable of inducing MMP-9 mRNA expression. This study demonstrates that platelet-derived EV can simultaneously activate MT1-MMPs and induce de novo expression of MMPs within cancer cells.
Collectively, these studies suggests that exosomes may be capable of direct contribution to matrix remodeling both within the tumor microenvironment and potentially at distant sites away from the primary tumor.
EXOSOME-REGULATED METABOLISM AND DRUG RESISTANCE
Altered cell metabolism is a hallmark of cancer, with many cancer cells demonstrating an increase of aerobic glycolysis. This results in subsequent lowering of pH, leading to increased tumor invasion, proliferation, migration and drug resistance [111, 112] . There is growing interest in the role of exosomes, and other EV, as modulators of cancer cell metabolism. It has been reported that pH of the tumor microenvironment is a key factor in regulating both the release and uptake of exosomes by cancer cells [113] , suggesting a positivefeedback mechanism resulting in elevated secretion of EV from the tumor microenvironment.
Several studies have demonstrated a link between altered cell metabolism and the development of multidrug resistance in multiple cancer types [114] [115] [116] , including prostate [117] . Prostate cancer progression is a complex process. In early stage disease the cancer remains androgen sensitive and can be treated with androgen-deprivation therapy. Over time, however, the cancer cells become androgen insensitive. Chemotherapeutic agents, such as docetaxel, can be used to treat androgen-independent disease [118] . By this stage, however, disease relapse is extremely likely and the development of multidrug resistant cancers results in impaired treatment. Several factors have been linked to multidrug resistance [119] including the overexpression of transporter proteins such as P-glycoprotein [120] , a well characterized ATP-binding cassette transporter that is involved in the transportation of various substances across the plasma membrane.
Drug-resistant prostate cancer cell lines can transfer drug resistance to non-resistant cells via uptake of exosomes [121] , and other EV [122] , shed from drugresistant cells. The initiation of drug-resistance is triggered by vesicular-mediated metabolic alteration of drug-sensitive cells towards a drug-resistant phenotype, with an increase in glycolysis and glycolytic capacity [123] . Such changes in metabolic profile may also be reflected in cargo of EV secreted from the cancer, and may represent a source of biomarkers useful for both diagnosis and monitoring prognosis of disease [124] .
In addition, cancer-associated fibroblasts can also regulate metabolic processes within neighboring cancer cells [125] . It was recently shown that cancerassociated fibroblast-derived exosomes can reprogram prostate cancer cell metabolism by downregulating mitochondrial function [126] . Specifically, fibroblastderived exosomes were shown to inhibit mitochondrial oxidative phosphorylation, resulting in an increase in glycolysis. This may be in part due to delivery of metabolite cargo consisting of lactate, acetate, amino acids, tricarboxylic acid cycle intermediates and lipids from fibroblast-exosomes [126] . Activated stromal cells therefore appear capable of inducing the Warburg effect [127, 128] , an increased rate of glycolysis followed by lactic acid fermentation, in surrounding cancer cells through EV mediated processes. Despite further studies being required to clarify the effects of metabolic change on cancer progression, stromal cell EV appear to contribute to cancer proliferation and survival in environments low in oxygen and nutrients.
CONCLUSION
As studies into the role of exosomes in prostate cancer continue, we are likely to learn of further ways in which exosomes regulate disease progression. Whilst studies specifically on prostate cancer/stromaderived exosomes may appear limited in number there is a great wealth of knowledge on the role of exosomes within other solid cancers that remain useful in informing us of the potential role of exosomes in prostate cancer [ Figure 1 ].
Prostate cancer exosomes have been shown to regulate angiogenesis, which may occur through exosome-mediated delivery of growth factors or RNAs. Prostate cancer exosomes have also been shown to further regulate the tumor microenvironment through activation of stromal cells to a disease-supporting myofibroblast-like phenotype and may be capable of modulating myeloid cells, thereby regulating immune and inflammatory responses within the tumor microenvironment. There is sufficient evidence to suggest that exosomes are capable of regulating cancer cell metabolism and tumor metastasis, and are capable of transferring drug resistance from one cell to another. Such exosome-mediated effects, may impact tumor progression through direct or indirect mechanisms. Furthermore, it is not just cancer cellderived exosomes, but also exosomes from other cell types within the tumor microenvironment, which may facilitate cancer progression. Whilst we may currently only be scratching the surface in terms of the possible roles for exosomes in prostate cancer, it is clear that exosomes are present and actively contribute to the disease process.
It remains unclear why some men with prostate cancer have slow growing, indolent, tumors whilst others develop aggressive late stage disease that is resistant to treatment. There is therefore a growing demand for improved assays capable of predicting those men who are likely to develop aggressive disease. Due to the elevated secretion of exosomes from neoplastic cells, their altered cargo, and their presence within numerous biological fluids, there is substantial interest in the use of exosomes as biomarkers for both diagnostic and prognostic monitoring of disease. Methodologies for Figure 1 : Overview of multiple roles of exosomes in prostate cancer. The previously described roles of prostate cancer exosomes are varied. Many other potential roles demonstrated for exosomes, and/or EV, from other cancer types may also be applicable to prostate cancer exosomes. Cancer exosomes can modulate the immune system. They can transmit tumor antigens to DC, or direct differentiation of myeloid cells towards MDSC/anti-inflammatory (M2) macrophage phenotypes. Exosome-mediated delivery of RNAs can induce endothelial cell proliferation, and exosome-associated proteins can induce endothelial tubule formation. Exosomal-TGFβ can induce differentiation of stromal fibroblasts or MSC towards a pro-angiogenic and tumor supporting myofibroblast-like phenotype. Stromal cell-derived EV can transfer chemoresistance to cancer cells and modulate both cancer cell metastasis and metabolism. Disease progression is further enhanced by cancer exosomes, which have been shown to drive extracellular matrix remodeling and impair osteoclastic differentiation. EV: extracellular vesicles; DC: dendritic cells; MDSC: myeloid-derived suppressor cell; MSC: mesenchymal stem cell; VEGF: vascular endothelial growth factor; MMP: matrix metalloproteinase; FAK: focal adhesion kinase; IGFR: insulin-like growth factor receptor; Src: protooncogene tyrosine-protein kinase Src; FGF2: fibroblast growth factor 2; uPA: urokinase-type plasminogen activator; HGF: hepatocyte growth factor, PDGF: platelet-derived growth factor; TGFβ: transforming growth factor beta isolation of exosomes from biofluids, such as urine and plasma [129] , already exist and early testing of exosomes as potential biomarkers of prostate cancer appear promising [130] . Further studies are however required to validate the clinical utility of such assays and to fully understand the relationship between EV, biomarkers, and disease outcome.
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